Alemtuzumab and stem cell transplantation versus non-induction therapies in multiple sclerosis

Takeaway

  • There is an increased incidence of thyroid disease with alemtuzumab (ATB), and of infection with autologous hematopoietic stem cell transplantation (AHSCT) compared with non-induction therapies in the treatment of patients with multiple sclerosis (MS).

Why this matters

  • In Sweden, ATB (monoclonal antibody, induces depletion and repopulation of CD52+ cells) and AHSCT are mainly used for aggressive relapsing MS; however, their widespread use is limited by concerns and uncertainty around their safety compared with other MS therapies.

  • The association of increased thyroid disease and infection risk with ATB and AHSCT complements current therapeutic knowledge, allowing clinicians and patients with MS to make more informed treatment decisions; and provides a basis for further study.